« Back
Sarepta Therapeutics Announces Recipients of LGMD Grant Awards for 2024; Program Supports Early Genetic Testing and Awareness
09/30/24 9:00 AM EDT
- Recipients awarded a total of more than $100,000 in grants
- Funding will support education and activities to shorten diagnostic journey
The grant program launched in 2022 and was created with the goal of shortening the LGMD diagnostic journey and enhancing participation in existing genetic testing programs so that families may benefit from earlier access to specialized care and increased clinical trial participation.
“Sarepta is excited to continue supporting organizations that align with our efforts to identify and address challenges facing the LGMD community as research suggests that less than a third of patients have a genetic diagnosis,” said
The grant program was open to non-governmental and patient advocacy organizations from any country or region. The following organizations are this year’s recipients:
- Asociación Distrofia Muscular, based in
Argentina , was founded in 1983 by individuals with neuromuscular disorders, their families, and healthcare professionals who specialized in these pathologies. The organization will use the grant to reach more patients inArgentina andLatin America and provide counseling and medical assistance and promote genetic testing. - GFB Onlus, based in
Italy , is dedicated to supporting and promoting research projects to treat LGMD and advance the needs of patients and their families. The organization will use the grant to build a network of educational groups for families in their local language, provide genetic testing education, and study the early signs and symptoms for people with a confirmed diagnosis.
All proposals were reviewed by the Sarepta Grants Committee. Organizations will have through 2025 to complete the activities described in their proposal. For more information about the program, visit www.sarepta.com/LGMDGrantAwardProgram or send an email to Advocacy@Sarepta.com.
About
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact:
iestepan@sarepta.com
Media Contact:
tsorrentino@sarepta.com
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.